Sanderling Ventures

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Metavention, Inc., incorporated in 2012 and based in Dover, Delaware, focuses on innovative treatments aimed at addressing metabolic diseases linked to overactive sympathetic nerves. The company has developed a renal denervation procedure utilizing its IRF denervation system, which applies radio frequency energy to specifically target these nerves. This approach is designed to provide a permanent solution for conditions such as high blood pressure and complications associated with Type 2 diabetes, including elevated glucose levels and abnormal liver function. By employing trans-catheter devices that leverage standard interventional vascular techniques, Metavention equips medical practitioners with effective tools for diagnosing and treating patients suffering from these metabolic disorders.

PreciThera, Inc. is a biotechnology company based in Montreal, Canada, dedicated to developing biological therapeutics for rare bone diseases. Founded in 2016, the company focuses on heterogeneous genetic disorders that primarily lead to bone dysfunction. By leveraging computational technology alongside a comprehensive understanding of disease pathology, PreciThera aims to create targeted therapies that address both skeletal and extraskeletal symptoms in affected patients. The company seeks to enhance treatment options through innovative approaches, including traditional protein replacement therapies, to improve the quality of life for individuals with these rare conditions.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

DalCor Pharmaceuticals is focused on developing precision treatments for cardiovascular disease by targeting specific genetic profiles to enhance clinical outcomes. Its primary program, dalcetrapib, aims to reduce cardiovascular events in patients with a distinct genetic marker. A pharmacogenomic analysis from a significant study indicated that patients with acute coronary syndrome possessing an AA polymorphism in the ADCY9 gene experienced fewer cardiovascular events when treated with dalcetrapib, a CETP inhibitor, compared to those receiving a placebo. The company has secured an exclusive worldwide license from Roche for dalcetrapib and the associated ADCY9 genetic marker. By integrating clinical, biological, and genetic insights, DalCor seeks to address the residual cardiovascular risk in genetically defined patient populations, thereby maximizing therapeutic benefits.

Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Liphorus Pharmaceuticals Inc. is a Montreal-based company founded in 2014 that specializes in the development of pharmaceuticals aimed at treating hypercholesterolemia. The company focuses on small molecules and therapeutic antibodies that target PCSK9, a protein involved in cholesterol regulation. Through innovative research agreements, including collaborations with the IRCM, Liphorus works to create and validate compounds that enhance the reduction of LDL cholesterol levels. Their approach aims to provide patients with effective oral administration options for managing their cholesterol levels.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

TheraVida, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic products for urological disorders and central nervous system conditions. Founded in 2005 and headquartered in California, TheraVida specializes in enhancing treatments for overactive bladder (OAB) and urge urinary incontinence. Its lead product, Tolenix, combines tolterodine, a muscarinic antagonist, with pilocarpine, a muscarinic agonist, to address OAB while mitigating the dry mouth side effects commonly associated with existing therapies. The company's innovative approach aims to improve the tolerability profile of anti-muscarinic treatments, enabling healthcare providers to offer effective solutions for patients dealing with these conditions.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Infraredx, Inc. is a cardiovascular imaging medical device company focused on diagnosing and treating coronary artery diseases. Based in Burlington, Massachusetts, the company specializes in near-infrared spectroscopy (NIRS) technology, offering products such as the dual-modality NIRS-intravascular ultrasound (IVUS) True Vessel Characterization Imaging System, which identifies and characterizes lipid core coronary plaques. Other key products include the Makoto intravascular imaging system, the Dualpro catheter that combines IVUS and NIRS capabilities, and optical catheters that provide high-resolution images of plaque structures. Infraredx serves hospital sites primarily in the United States and Europe, and it operates as a subsidiary of Goodman USA, Inc. after being founded in 1998 and rebranding from InfraReDx, Inc. in 2012.

Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Gemin X Pharmaceuticals focuses on the discovery, development, and commercialization of innovative cancer therapeutics aimed at enhancing patient outcomes. The company's research has centered on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070 (obatoclax), a small molecule designed to selectively trigger programmed cell death, or apoptosis, and potentially induce cancer cell autophagy. Obatoclax has demonstrated promising results in preclinical and early clinical trials and is currently undergoing Phase 2 clinical trials as both a standalone treatment and in combination with other therapies. Additionally, Gemin X is involved in developing other oncology products, including GMX1777, which inhibits NAD+ synthesis. The patent for obatoclax is secured until 2025, reinforcing the company's commitment to advancing cancer treatment options.

Taligen Therapeutics is dedicated to discovering and developing innovative protein therapeutics aimed at modulating the alternative pathway of the complement system. This approach targets a range of inflammatory conditions and diseases. The company's primary therapeutic candidates include monoclonal antibodies and recombinant fusion proteins designed to address key factors in the alternative pathway, which has been identified as a significant mechanism in the inflammatory response. By focusing on the regulation of the complement system, Taligen Therapeutics seeks to create effective treatments for various inflammatory and immune diseases.

TheraVida, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic products for urological disorders and central nervous system conditions. Founded in 2005 and headquartered in California, TheraVida specializes in enhancing treatments for overactive bladder (OAB) and urge urinary incontinence. Its lead product, Tolenix, combines tolterodine, a muscarinic antagonist, with pilocarpine, a muscarinic agonist, to address OAB while mitigating the dry mouth side effects commonly associated with existing therapies. The company's innovative approach aims to improve the tolerability profile of anti-muscarinic treatments, enabling healthcare providers to offer effective solutions for patients dealing with these conditions.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Gemin X Pharmaceuticals focuses on the discovery, development, and commercialization of innovative cancer therapeutics aimed at enhancing patient outcomes. The company's research has centered on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070 (obatoclax), a small molecule designed to selectively trigger programmed cell death, or apoptosis, and potentially induce cancer cell autophagy. Obatoclax has demonstrated promising results in preclinical and early clinical trials and is currently undergoing Phase 2 clinical trials as both a standalone treatment and in combination with other therapies. Additionally, Gemin X is involved in developing other oncology products, including GMX1777, which inhibits NAD+ synthesis. The patent for obatoclax is secured until 2025, reinforcing the company's commitment to advancing cancer treatment options.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company utilizes its proprietary platform technology, Pro/PEG, which is a bioadhesive polymer hydrogel. Neomend specializes in a combination wound sealant and adhesion barrier product designed for use during minimally invasive or laparoscopic surgical procedures, aiming to enhance patient outcomes and improve recovery times.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

NovoStent Corporation, a medical device company that has developed a novel "anchored" helical stent technology to provide a wide range of vascular therapies.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

Axikin Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, dedicated to the development and commercialization of small molecule therapeutics targeting respiratory, inflammatory, and autoimmune diseases. Founded in 2008, Axikin focuses on innovative treatments for conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease, and rheumatoid arthritis. The company's efforts include the development of novel therapeutics that aim to enhance treatment options for severe respiratory disorders and reduce inflammation. Axikin was established as a spin-off from Actimis Pharmaceuticals and continues to strive for advancements in healthcare solutions for complex diseases.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, that specializes in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism spectrum disorders (ASDs). Founded in 2002, Lineagen offers several key products, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes associated with autism, and NextStepDx PLUS, a genetic sequencing test that detects small genomic alterations. Additionally, the company provides M-CHAT.org, an online tool for developmental screening. Lineagen aims to improve outcomes for individuals affected by complex diseases through early diagnosis and intervention, leveraging extensive proprietary research and access to the Utah Population Database to enhance its understanding of genetic contributions to these conditions. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Pacira BioSciences Inc. is a pharmaceutical company based in San Diego, California, specializing in non-opioid pain management and regenerative health solutions. Founded in 1989, it develops and manufactures injectable pharmaceutical products aimed at improving outcomes for healthcare practitioners and their patients. Pacira's portfolio includes three commercialized non-opioid treatments: EXPAREL, a long-acting local analgesic approved for postsurgical pain management; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis; and iovera, a handheld device that provides immediate, long-lasting, drug-free pain relief through controlled cold temperature delivery to targeted nerves.

ISTA Pharmaceuticals is a commercial-stage pharmaceutical company based in Irvine, California, focused on developing and marketing treatments for various eye diseases and conditions. Founded in 1992, the company specializes in remedies for ocular inflammation, glaucoma, dry eye, and allergies. Its marketed products include BROMDAY, an ophthalmic solution for postoperative inflammation and pain, BEPREVE for allergic conjunctivitis, ISTALOL for glaucoma, and VITRASE, used as a spreading agent in ocular treatments. ISTA is also engaged in developing several products, including over-the-counter artificial tears, PROLENSA for postoperative pain relief, and various nasal sprays for allergic rhinitis. The company sells its products to a broad range of customers, including drug wholesalers, retail pharmacies, hospitals, and managed healthcare providers. As of June 2012, ISTA Pharmaceuticals operates as a subsidiary of Bausch & Lomb Incorporated.

Altor BioScience Corporation, founded in 2002 and based in Miramar, Florida, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of immunotherapeutic agents aimed at treating cancer, viral infections, and autoimmune diseases. The company’s product portfolio includes several innovative candidates such as ALT-801, a T-cell receptor-targeted treatment for cancer, and ALT-803, an IL-15 superagonist for solid tumors and metastatic melanoma. Altor also develops novel monoclonal antibodies and fusion proteins, targeting conditions such as acute respiratory distress syndrome and non-small cell lung cancer. Additionally, the company offers STAR Fusion and STAR Multimer Reagents, which are utilized for the diagnosis and targeting of cancer and viral infections, as well as for research in vaccine development. Altor BioScience's focus on the immunostimulatory properties of cytokines like IL-15 and IL-2 underlines its commitment to enhancing the immune response against diseases.

Gemin X Pharmaceuticals focuses on the discovery, development, and commercialization of innovative cancer therapeutics aimed at enhancing patient outcomes. The company's research has centered on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070 (obatoclax), a small molecule designed to selectively trigger programmed cell death, or apoptosis, and potentially induce cancer cell autophagy. Obatoclax has demonstrated promising results in preclinical and early clinical trials and is currently undergoing Phase 2 clinical trials as both a standalone treatment and in combination with other therapies. Additionally, Gemin X is involved in developing other oncology products, including GMX1777, which inhibits NAD+ synthesis. The patent for obatoclax is secured until 2025, reinforcing the company's commitment to advancing cancer treatment options.

Actimis Pharmaceuticals, Inc. is a start-up biopharmaceutical company dedicated to developing small molecule therapeutics aimed at treating respiratory and inflammatory disorders. Founded by Dr. Kevin Bacon as a spin-off from Bayer Healthcare AG's research portfolio, Actimis focuses on conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease, and rheumatoid arthritis. The company aims to provide effective treatment options for these diseases, enabling physicians to improve patient outcomes. Actimis has secured venture financing from a syndicate led by Sanderling Ventures and Mitsui & Co Venture Partners, facilitating its ambitious development initiatives.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

Asteres Inc., based in San Diego, California, specializes in pharmacy automation technology, focusing on the development and installation of kiosks and lockers for prescription and healthcare product pickup. Founded in 2003, the company offers several solutions, including ScriptCenter, an automated pharmacy pickup system that allows consumers to collect their prescriptions and OTC medications conveniently without waiting in line, even outside of pharmacy hours. Additionally, Asteres provides the Scriptcenter MX kiosk for automated pickup and payment of prescriptions and the ScriptCenter Locker System, designed for various volume needs and space constraints. The company's technology enhances the retail pharmacy experience by extending pickup hours without increasing staffing requirements and reducing congestion at pharmacy counters. Asteres also delivers IT integration, pharmacy management, marketing, branding, and ongoing support services, drawing on the management team's extensive experience in healthcare automation.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Infraredx, Inc. is a cardiovascular imaging medical device company focused on diagnosing and treating coronary artery diseases. Based in Burlington, Massachusetts, the company specializes in near-infrared spectroscopy (NIRS) technology, offering products such as the dual-modality NIRS-intravascular ultrasound (IVUS) True Vessel Characterization Imaging System, which identifies and characterizes lipid core coronary plaques. Other key products include the Makoto intravascular imaging system, the Dualpro catheter that combines IVUS and NIRS capabilities, and optical catheters that provide high-resolution images of plaque structures. Infraredx serves hospital sites primarily in the United States and Europe, and it operates as a subsidiary of Goodman USA, Inc. after being founded in 1998 and rebranding from InfraReDx, Inc. in 2012.

Taligen Therapeutics is dedicated to discovering and developing innovative protein therapeutics aimed at modulating the alternative pathway of the complement system. This approach targets a range of inflammatory conditions and diseases. The company's primary therapeutic candidates include monoclonal antibodies and recombinant fusion proteins designed to address key factors in the alternative pathway, which has been identified as a significant mechanism in the inflammatory response. By focusing on the regulation of the complement system, Taligen Therapeutics seeks to create effective treatments for various inflammatory and immune diseases.

Asteres Inc., based in San Diego, California, specializes in pharmacy automation technology, focusing on the development and installation of kiosks and lockers for prescription and healthcare product pickup. Founded in 2003, the company offers several solutions, including ScriptCenter, an automated pharmacy pickup system that allows consumers to collect their prescriptions and OTC medications conveniently without waiting in line, even outside of pharmacy hours. Additionally, Asteres provides the Scriptcenter MX kiosk for automated pickup and payment of prescriptions and the ScriptCenter Locker System, designed for various volume needs and space constraints. The company's technology enhances the retail pharmacy experience by extending pickup hours without increasing staffing requirements and reducing congestion at pharmacy counters. Asteres also delivers IT integration, pharmacy management, marketing, branding, and ongoing support services, drawing on the management team's extensive experience in healthcare automation.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company utilizes its proprietary platform technology, Pro/PEG, which is a bioadhesive polymer hydrogel. Neomend specializes in a combination wound sealant and adhesion barrier product designed for use during minimally invasive or laparoscopic surgical procedures, aiming to enhance patient outcomes and improve recovery times.

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Xytis is a biopharmaceutical company focusing on the discovery and development of innovative CNS drug candidates. The company is privately held and was created in Jan 2006 by the merger of Xytis Pharmaceuticals Ltd. (UK) and Remergent, Inc. (USA). The company received funding from Sanderling Ventures, Atlas Venture, CDC Entreprises Innovation, and Ventech. Xytis Inc. is assembling a pipeline of innovative compounds with validated mechanisms of action, addressing major unmet clinical needs in CNS fields such as Schizophrenia, Traumatic Brain Injury, Depression, Anxiety, or Insomnia. The company has two clinical stage compounds in development and operates from the USA, UK and Switzerland.

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

Infraredx, Inc. is a cardiovascular imaging medical device company focused on diagnosing and treating coronary artery diseases. Based in Burlington, Massachusetts, the company specializes in near-infrared spectroscopy (NIRS) technology, offering products such as the dual-modality NIRS-intravascular ultrasound (IVUS) True Vessel Characterization Imaging System, which identifies and characterizes lipid core coronary plaques. Other key products include the Makoto intravascular imaging system, the Dualpro catheter that combines IVUS and NIRS capabilities, and optical catheters that provide high-resolution images of plaque structures. Infraredx serves hospital sites primarily in the United States and Europe, and it operates as a subsidiary of Goodman USA, Inc. after being founded in 1998 and rebranding from InfraReDx, Inc. in 2012.

Actimis Pharmaceuticals, Inc. is a start-up biopharmaceutical company dedicated to developing small molecule therapeutics aimed at treating respiratory and inflammatory disorders. Founded by Dr. Kevin Bacon as a spin-off from Bayer Healthcare AG's research portfolio, Actimis focuses on conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease, and rheumatoid arthritis. The company aims to provide effective treatment options for these diseases, enabling physicians to improve patient outcomes. Actimis has secured venture financing from a syndicate led by Sanderling Ventures and Mitsui & Co Venture Partners, facilitating its ambitious development initiatives.

Asteres Inc., based in San Diego, California, specializes in pharmacy automation technology, focusing on the development and installation of kiosks and lockers for prescription and healthcare product pickup. Founded in 2003, the company offers several solutions, including ScriptCenter, an automated pharmacy pickup system that allows consumers to collect their prescriptions and OTC medications conveniently without waiting in line, even outside of pharmacy hours. Additionally, Asteres provides the Scriptcenter MX kiosk for automated pickup and payment of prescriptions and the ScriptCenter Locker System, designed for various volume needs and space constraints. The company's technology enhances the retail pharmacy experience by extending pickup hours without increasing staffing requirements and reducing congestion at pharmacy counters. Asteres also delivers IT integration, pharmacy management, marketing, branding, and ongoing support services, drawing on the management team's extensive experience in healthcare automation.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Artielle ImmunoTherapeutics, Inc. is a biopharmaceutical company based in Tigard, Oregon, established in 2004. The company develops a platform of biologic drugs designed to address inflammatory and degenerative diseases, particularly neuro-inflammatory conditions. Artielle's focus includes multiple sclerosis, optic neuritis, methamphetamine addiction, stroke, rheumatoid arthritis, uveitis, age-related macular degeneration, and celiac disease. The company's lead compound, RTL1000, targets T-cell mediated inflammatory diseases by utilizing recombinant T-cell receptor ligands (RTLs). By blocking the action of macrophage migration inhibitory factor through its biological platform, Artielle aims to provide innovative treatments for a range of autoimmune disorders, contributing to advancements in the healthcare industry.

Zapaq, Inc. is a privately held biopharmaceutical company focused on discovering an developing therapeutics that target aspartic proteases, a group of enzymes central to a variety of human diseases, including Alzheimer's. The company is headquartered in Waltham, MA and has research and development operations in Oklahoma City, OK.

CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.

Kadmus Pharmaceuticals, Inc., a biopharmaceutical company, commercially exploits endocannabinoid pathways to develop therapeutics. Endocannabinoids are naturally occurring signaling molecules, whose functions include regulating mood, pain, and metabolism. It offers a portfolio of compounds with activity against a range of disorders targeting CNS conditions, metabolic disorders, neuropathic pain, and obesity. The company develops products for various conditions through the inhibition of endocannabinoid degradation and activation of endocannabinoid related pathways and peripheral cannabinoid receptors. It operates in the United States, Canada, and Europe. Kadmus Pharmaceuticals, Inc. was founded in 1998 and is based in Irvine, California.

Asteres Inc., based in San Diego, California, specializes in pharmacy automation technology, focusing on the development and installation of kiosks and lockers for prescription and healthcare product pickup. Founded in 2003, the company offers several solutions, including ScriptCenter, an automated pharmacy pickup system that allows consumers to collect their prescriptions and OTC medications conveniently without waiting in line, even outside of pharmacy hours. Additionally, Asteres provides the Scriptcenter MX kiosk for automated pickup and payment of prescriptions and the ScriptCenter Locker System, designed for various volume needs and space constraints. The company's technology enhances the retail pharmacy experience by extending pickup hours without increasing staffing requirements and reducing congestion at pharmacy counters. Asteres also delivers IT integration, pharmacy management, marketing, branding, and ongoing support services, drawing on the management team's extensive experience in healthcare automation.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Infraredx, Inc. is a cardiovascular imaging medical device company focused on diagnosing and treating coronary artery diseases. Based in Burlington, Massachusetts, the company specializes in near-infrared spectroscopy (NIRS) technology, offering products such as the dual-modality NIRS-intravascular ultrasound (IVUS) True Vessel Characterization Imaging System, which identifies and characterizes lipid core coronary plaques. Other key products include the Makoto intravascular imaging system, the Dualpro catheter that combines IVUS and NIRS capabilities, and optical catheters that provide high-resolution images of plaque structures. Infraredx serves hospital sites primarily in the United States and Europe, and it operates as a subsidiary of Goodman USA, Inc. after being founded in 1998 and rebranding from InfraReDx, Inc. in 2012.

CyThera, Inc., headquartered in San Diego, CA, is a biotechnology company focused on developing cell replacement therapies for the treatment of human degenerative diseases. The company's proprietary technology platform enables the expansion and proliferation of functional human cells that can be used to treat human degenerative disease.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.

Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.

Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cardio-renal diseases. The company's product pipeline features adenosine agonists and antagonists aimed at treating cardiovascular conditions, alongside leukotriene synthesis inhibitors for chronic renal diseases. Aderis focuses on creating small-molecule, receptor-specific therapeutics that modulate the activity of proteins like adenosine and dopamine, thereby enhancing therapeutic effects while reducing side effects. Additionally, Aderis has established license agreements with strategic partners for advanced products targeting Parkinson's disease and for the diagnosis of coronary artery disease.

Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.

Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.

BioSpace Inc., headquartered in Englewood, Colorado with a satellite office in San Francisco, operates BioSpace.com, an online platform dedicated to serving the life science community. It offers an extensive job board, daily news feeds, and community features that facilitate connections among recruiters, job seekers, and professionals in biotechnology, pharmaceuticals, medical devices, diagnostics, clinical research, academia, and biomedical industries across North America. BioSpace also hosts career events for recruitment professionals. Formerly a subsidiary of DHI Group Inc., the company aims to accelerate communication and discovery within the life science sector by providing essential insights, opportunities, and tools for both innovative organizations and talented professionals worldwide.

CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.

Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.